Physician profile
Astrid Lied
NPI 1548034416
$7,273.08
in general payments reported to CMS, 2019-2025
42 companies · $5,508 in 2025
The $5,508 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,766 · 2025: $5,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.18 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,188.64 | 2024-2025 | Ingrezza |
| Abbvie INC. | $956.20 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $550.95 | 2024-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $500.37 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $422.72 | 2024-2025 | Hyqvia |
| Tg Therapeutics, INC. | $383.72 | 2025 | |
| Biogen, INC. | $319.61 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Genentech USA, INC. | $292.90 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Lilly USA, LLC | $249.33 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Lundbeck LLC | $223.17 | 2024-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $202.44 | 2024-2025 | |
| Argenx US, INC. | $182.02 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $181.89 | 2024-2025 | |
| Eisai INC. | $179.53 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $158.46 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Lied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.